Ligand id: 6593

Name: efalizumab

No information available.
Summary of Clinical Use
Used to treat psoriasis prior to withdrawl from the market.
Mechanism Of Action and Pharmacodynamic Effects
The molecular target of this monoclonal antibody is ITGAL (integrin alpha L subunit, lymphocyte function associated antigen 1, aka CD11a). The antibody acts as an immunosuppressant by inhibiting lymphocyte activation and cell migration out of blood vessels into tissues.